There are 511 resources available
59P - Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib 960mg (soto960) plus panitumumab (pani) vs trifluridine/tipiracil(T/T) plus bevacizumab (bev) in chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Lisa Salvatore
Session: Poster Display session
Resources:
Abstract
60P - Comparison of the efficacy of third-line treatments for metastatic colorectal cancer: A network meta-analysis
Presenter: Julien Taieb
Session: Poster Display session
Resources:
Abstract
61P - Safety and efficacy of encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: A systematic review and single-arm meta-analysis
Presenter: Davi Said Celso
Session: Poster Display session
Resources:
Abstract
62P - Efficacy of neoadjuvant chemotherapy in patients (pts) with locally advanced colon cancer (LACC) in the different subgroups: Results of the meta-analysis
Presenter: Mikhail Fedyanin
Session: Poster Display session
Resources:
Abstract
63P - FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only (LL), right-sided and/or RAS or BRAF mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials
Presenter: Federica Marmorino
Session: Poster Display session
Resources:
Abstract
64P - Long-term response to regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A systematic literature review (SLR)
Presenter: Marc Peeters
Session: Poster Display session
Resources:
Abstract
65P - Costs and resource utilization in the curative and palliative treatment phases of metastatic colorectal cancer: Patient-level data analysis of the Finnish RAXO study
Presenter: Pia Osterlund
Session: Poster Display session
Resources:
Abstract
66P - Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC)
Presenter: Margherita Ambrosini
Session: Poster Display session
Resources:
Abstract
67P - Relevance of local treatment with curative intent (LT) against metastatic colorectal cancer (mCRC): Findings of a retrospective cohort study at the Comprehensive Cancer Center Munich (CCC MunichLMU)
Presenter: Jo-Ann Eisenburger
Session: Poster Display session
Resources:
Abstract
68P - Post-treatment ctDNA analysis reveals patterns of HER2 therapy resistance in advanced HER2-amplified colorectal cancer
Presenter: Celine Hoyek
Session: Poster Display session
Resources:
Abstract